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Abstract 
PARK7 (also called DJ-1 or Parkinsonism 
associated deglycase) is a pleiotropic protein 
belonging to the peptidase C56 family. It acts as 
positive regulator of androgen receptor-dependent 
transcription, redox-sensitive chaperone, sensor for 
oxidative stress, and apparently protects neurons 
against oxidative stress and cell death. Dysfunctions 
in PARK7 are related to autosomal recessive early-
onset Parkinson disease 7 and cancer forms. Here, 
we review some major data on PARK7, concerning 
the genetic structure, the transcription regulation, the 
encoded protein and functions, and its implication in 
human diseases. 
Keywords: PARK7, DJ-1, Autosomal Recessive 
Early-Onset Parkinson Disease, Oncogene 
Identity 
Other names: DJ1, DJ-1, HEL-S-67p, RS, CAP1, 
FLJ27376, FLJ92274, FLJ34360 
HGNC (Hugo): PARK7 
Location: Location Cytogenetic location: 1p36.23; 
Molecular location: Chromosome 1; Start 7961654; 
Stop 7985282based on Genome Browser Human 
Dec. 2013 (GRCh38/hg38) Assembly [Link to 
chromosome band 1p36] 
Local order: PARK7 is flanked towards the 
telomeric direction by two protein-coding genes 
(UTS2 and TNFRSF9) and towards the centromeric 
direction by ERRFI1. According to NCBI 
MapViewer, a non-coding RNA (LOC105376694) is 
also present in this locus (Figure 1). 
Figure 1 displays the human chromosome 1 (NCBI Reference Sequence NC_000001.11) and relative localization and orientation 
of PARK7 and flanking genes. PARK7 is represented in red. Further genes (UTS2, TNFRSF9, ERRFI1) and a non-coding RNA 
(LOC105376694) map in this locus. 
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Figure 2 displays the two full-length Reference Sequences of PARK7 gene (NCBI - Nucleotide Database). Corresponding 
GenBank Accession Numbers are indicated on the left. Exons are represented as boxes (blue for coding regions and white for 
non-coding), whereas the dashed line indicates intronic regions. The green triangle specifies the start codon, while the red one 




DJ-1 maps on the distal part of the short arm of 
chromosome 1, cytoband 1p36.23 (Figure 1). It 
spans about 24 kb and includes eight exons (Figure 
2). The first two exons (1A and 1B) are noncoding 
and alternatively spliced in the DJ-1 mRNAs 
(Bonifati, Rizzu, Squitieri, et al., 2003). 
Transcription 
Currently, the NCBI RefSeq database annotates two 
representative transcripts as full-length PARK7 
mRNAs (Figure 2). However, a total of 10 spliced 
variants is reported in the Ensembl database 
http://www.ensembl.org (Figure 3). The majority of 
mRNAs contain a 570 bp ORF, encoding a protein 
of 189 aa. Two shorter transcripts (PARK7-003 
lacking exon 4, and PARK7-010 starting at an inner 
transcription point) produce smaller proteins (169 
and 160 aa respectively) (Table 2 and Fig. 3). Other 
transcripts do not encode proteins and are processed 
via the NMD (non-sense mediated decay) 
mechanism. 
Pseudogene 
PGOHUM00000239770: Chr. 12, Start Coordinate 
49988931, Stop Coordinate 49989471 according 
toGenome BrowserHuman Dec. 2013 
(GRCh38/hg38) Assembly 
PGOHUM00000236716: Chr. 9, Start Coordinate  
98680419, Stop Coordinate 98680983according to 




X-ray crystallographic examination of DJ-1 protein 
structure indicates that it exists as a dimer (Figure 
4)(Wilson et al., 2003). It contains domains found in 
heat shock chaperones and belongs to the ThiJ/PfpI 
family. This family (pfam01965) includes: ThiJ, a 
protein involved in thiamine biosynthesis in 
prokaryotes; PfpI (so-called from P. furious protease 
I) and other bacterial proteases; araC and other 
bacterial transcription factors; and the glutamine 
amidotransferases family (including bacteria 
catalases) (Bonifati, Rizzu, Squitieri, et al., 2003). 
Expression 
DJ-1 is a ubiquitous protein, highly expressed in 
almost all cells and tissue (Figure 5). Distribution 
studies indicate that DJ-1 is preferentially expressed 
in testis, brain and kidney. In the brain, DJ-1 is 
expressed in both neurons and glial cells. The 
expression level of DJ-1 is increased under oxidative 
stress conditions both in PD and other 
neurodegenerative diseases(Ariga et al., 2013). DJ-1 
is also frequently overexpressed in the several tumor 






#  Name  Ensembl Transcript ID bp  Biotype  Protein  
1  PARK7-004  ENST00000493373  624  Protein coding  189aa  
2  PARK7-002  ENST00000338639  949  Protein coding  189aa  
3  PARK7-007  ENST00000460192  567  Processed transcript  No protein  
4  PARK7-001  ENST00000493678  1088  Protein coding  189aa  
5  PARK7-003  ENST00000377493  795  Protein coding  169aa  
6  PARK7-008  ENST00000465354  949  Processed transcript  No rotein  
7  PARK7-005  ENST00000377491  977  Protein coding  189aa  
8  PARK7-006  ENST00000377488  783  Protein coding  189aa  
9  PARK7-009  ENST00000497113  670  Processed transcript  No protein  
10  PARK7-010  ENST00000469225  711  Protein coding  160aa  
Table 1. 
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Figure 3 displays the structures of the currently known PARK7 mRNA splicing variants listed in Ensembl. Each mRNA variant is 
indicated with a number corresponding to that indicated in Table 1. Transcript variants are classified as coding mRNAs (black) 
and non-coding (gray). 
 
Localisation 
Subcellular localization: DJ-1 is mainly localized in 
the nucleus, cytoplasm, and mitochondria and is 
secreted into culture medium or serum, 
cerebrospinal fluid, saliva and nipple fluid(Ariga, 
2015). DJ-1 is translocated from the cytoplasm to 
nucleus upon addition of a mitogen to the culture 
medium, while it translocates to mitochondria after 
oxidative stress (Junn et al., 2009). 
Function 
The product of DJ-1 is an 189 amino acidic highly 
conserved multifunctional protein belonging to the 
peptidase C56 family (Lev et al., 2006). It mainly 
acts as regulator of transcription, redox-sensitive 
chaperone, sensor for oxidative stress, cysteine 
protease, and seems to protect neurons from ROS-
induced apoptosis (Figure 7) (Xu et al., 2005; Ariga 
et al., 2013). 
The oxidative stress sensor activity is carried out by 
three cysteine residues at C46, C53 and C106: under 
oxidative stress conditions, C106 is firstly oxidized 
from SH to SOH, SO2H and to SO3H form. The 
other cysteine residues then follow the same process 
of oxidation.  
The regulation of transcription is mediated by DJ-1 
binding with various transcription factors without 
directly tie up to DNA. Transcription factors or 
modified proteins identified so far include TP53, the 
androgen receptorAR and its regulatory proteins, the 
polypyrimidine tract-binding protein-associated 
splicing factor(SFPQ), KEAP1, an inhibitor for 
nuclear factor erythroid-2 related factor 2 (NFE2L2), 
the sterol regulatory element-binding protein 
(SREBP), Ras-responsive element-binding protein 
(RREB1), and signal transducer and activator of 
transcription1 (STAT1) (Ariga, 2015). 
DJ-1 is also involved in the activation or repression 
of cell growth and cell death signaling pathways. 
Specifically, this polypeptide modulates p53 
activity, the PI3K/Akt pathway by interacting with 
PTEN, and intervenes in the Raf/Erk pathway 
together with ras (Ariga, 2015). To this regard, it 
should be reminded that the first identified DJ-1 
function was its oncogene activity transforming 
mouse NIH3T3 cells in cooperation with activated 
ras (Nagakubo et al., 1997). 
 
 
Figure 4 shows the crystallographic structure of DJ-1 protein. This protein is a dimer composed of two portions, monomer A 
represented in purple and monomer B represented in green. Adapted from (Wilson et al., 2003). 
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Figure 5 (adapted from PROTEOMICS DB - www.proteomicsdb.org) shows the central and peripheral distribution of DJ-1 in 
human tissues. It is a ubiquitous protein, expressed in almost all human body systems. 
 
 
Figure 6 (fromGeneCards database http://www.genecards.org/ and based on Compartments http://compartments.jensenlab.org/) 
shows the subcellular localizations of DJ-1 into cellular structures. Data are derived from database annotations, automatic text 
mining of the biomedical literature, and sequence-based predictions. The confidence of each association is indicated with 
numbers (the higher number corresponds to a greater confidence). 
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Figure 7 summarizes the functions of DJ-1 and related 
diseases. It is though that excess of activation or loss of 
function of DJ-1 triggers the onset of various diseases, 
including cancer and oxidative stress-related diseases. 
Abbreviations: PD - Parkinson's Disease, FAP - familial 
amyloid polyneuropathy; COPD - chronic obstructive 
pulmonary disease. Adapted from (Ariga, 2015). 
Homology 
The PARK7 Gene Tree shows a great evolutionary 
conservation across species (Figure 8). The internal 
nodes of the phylogenetic tree are annotated for 
duplication (red boxes) and speciation (blue boxes) 




See Table 2. 
Germinal 
A wide spectrum of mutations in PARK7 have been 
identified in familial Parkinson's Disease patients 
from different ethnicities. Mutations include 
missense mutations in coding and UTR regions, 
frame-shifts, copy number variations, and splice 
sites alterations (Table 2). 
Somatic 
Along with the germinal mutations occurring in 
Parkinson's Disease, genetic defects have also been 
observed in solid tumors. A list of the known cancer-
derived mutations is available at the COSMIC 
Database and is summarized in Figure 9. 
Epigenetics 




Mutations in PARK7 are the less common cause of 
autosomal recessive Parkinsonism (~ 1% of early-
onset PD) (Lockhart et al., 2004; Moore et al., 2005).  
The first identified mutations were a large 
homozygous deletion and a missense mutation 
(L166P) identified in both Italian and Dutch 
consanguineous families (van Duijn et al., 2001; 
Bonifati, Rizzu, Squitieri, et al., 2003). The other 
observed familial mutations are summarized in 
Table 2. 
Familial amyloid polyneuropathy 
Transthyretin (TTR), a protein causing familial 
amyloidotic polyneuropathy (FAP), is a substrate of 
DJ-1 protease (Koide-Yoshida et al., 2007). In 
normal conditions, both TTR and DJ-1 are secreted 
into the culture medium. Under oxidative stress, 
TTR but not DJ-1 is secreted into the culture 
medium, resulting in the aggregation of TTR protein. 
Mirror images of both the expression patterns and 
solubility of DJ-1 and TTR have been observed in 
tissues of FAP patients, and the unoxidized form of 
DJ-1 is secreted into the serum of FAP patients. 
These results suggest that oxidative stress abrogates 
secretion of DJ-1 and that secreted DJ-1 degrades 
aggregated TTR to protect against the onset of FAP 
(Koide-Yoshida et al., 2007). 
Chronic obstructive pulmonary 
disease 
Disease 
Chronic obstructive pulmonary disease (COPD) is 
caused by cigarette smoking and oxidative stress. 
Malhotra et al. assessed the expression of NFE2L2 
(NRF2) and DJ-1 in non-COPD and smoker COPD 
lungs and in cigarette smoke-exposed human lung 
epithelial cells (Beas2B) and mice (Malhotra et al., 
2008). COPD patient lungs showed significantly 
decreased DJ-1 levels.  
Exposure of Bea2B cells to cigarette smoke caused 
oxidative modification and enhanced proteasomal 
degradation of DJ-1 protein. Disruption of DJ-1 in 
mouse lungs, mouse embryonic fibroblasts, and 
Beas2B cells lowered NRF2 protein stability and 
impaired antioxidant induction in response to 
cigarette smoke. Overall, DJ-1 expression was 
negatively associated with severity of COPD 










Atlas Genet Cytogenet Oncol Haematol. 2016; 20(12) 600 
 
  
PARK7 Mutations  Exon References 
Ex1-5del(g.07561_21658del14098) EX1-5 (Bonifati, Rizzu, van Baren, et al., 2003) 
Ex1-5dup (breakpoints not mapped) EX1-5 (Macedo et al., 2009) 
Ex2del (breakpoints not mapped) EX2 (Guo et al., 2010) 
Ex5del (breakpoints not mapped) EX5 (Djarmati et al., 2004) 
Ex5-7del (breakpoints not mapped) EX5-7 (Hedrich et al., 2004) 
c.-122_-107del (g.10539_10554del16) 5'UTR (Keyser et al., 2009) 
Leu10Pro (g.11658T>C) EX2 (Guo et al., 2008) 
Met26Ile (g.11707G>A) EX2 (Abou-Sleiman et al., 2003) 
Ala39Ser (g.14192G>T) EX3 (Tang et al., 2006) 
Glu64Asp (g.14269G>C) EX3 (Hering et al., 2004) 
Gly78 (g.18230C>T) EX2 (Abou-Sleiman et al., 2003) 
IVS4+8_9insA (g.18256_18257insA) IVS4 (Tarantino et al., 2009) 
Arg98Gln (g.19778G>A) EX5 
(Abou-Sleiman et al., 2003), (Lockhart et al., 
2004), (Healy et al., 2004), (Clark et al., 
2004), (Pankratz et al., 2006) 
Arg98(g.19779G>A) EX5 (Abou-Sleiman et al., 2003) 
Ala104Thr(g.19795G>A) EX5 Clark et al., 2004) 
IVS5+2_12del (g.19809_19819del11) IVS5 (Hedrich et al., 2004) 
Asp149Ala (g.33774A>C) EX7 (Abou-Sleiman et al., 2003) 
Pro158del (g.33799_33801delGCC) EX7 Macedo et al., 2009) 
Thr160 (g.33808C>A) EX7 (Pankratz et al., 2006) 
Glu163Lys (g.33815G>A) EX7 (Annesi et al., 2005) 
Leu166Pro (g.33825T>C)  EX7 (Bonifati, Rizzu, van Baren, et al., 2003)  
Ala167 (g.33829A>G) EX7  (Abou-Sleiman et al., 2003) 
Ala171Ser (g.33839G>T) EX7 (Clark et al., 2004) 
Lys175Glu (g.33851A>G) EX7 (Nuytemans et al., 2009) 
Ala179Thr (g.33863G>A) EX7 
(Macedo et al., 2009) , (Nuytemans et al., 
2009) 
Val186 (g.33886T>C) EX7 (Hering et al., 2004) 
c.*120insA (g.34018_34019insA) EX7 (Abou-Sleiman et al., 2003) 
c.*203G>A (g.34101G>A) EX7 (Abou-Sleiman et al., 2003) 
Table 2 displays the currently known PARK7 genetic mutations related to familial Parkinson's Disease. Details 
are available at the Parkinson Disease Mutation Database (http://www.molgen.vib-ua.be/PDMutDB/). 
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Figure 8. The PARK7 Gene Tree shows the maximum likelihood phylogenetic tree representing the evolutionary history of this 
gene, constructed using the alignment of a representative protein for each species (green bars). This Gene tree has been 
generated by Ensembl (GeneTree ENSGT00390000001231). 
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Figure 9 shows the overall distribution of PARK7 somatic mutations in cancer listed in COSMIC Database 
(http://cancer.sanger.ac.uk/cosmic) (March 2016). The exact number of collected somatic mutations in different cancer types is 
indicated in the data labels. 
 
Type II Diabetes 
The expression of DJ-1 is reduced in pancreatic islets 
of patients with type 2 diabetes mellitus (T2DM). 
Under non-diabetic conditions, DJ-1 expression 
increases in mouse and human islets during aging. 
Jain et al. demonstrated that, in mouse islets, DJ-1 
prevents an increase in reactive oxygen species and 
preserves mitochondrial integrity and physiology, 
prerequisites for glucose-stimulated insulin 
secretion(Jain et al., 2012). Accordingly, DJ-1-
deficient mice developed glucose intolerance and 
reduced βcell area as they age or gain weight. These 
data suggested that DJ-1 is more generally involved 
in age- and lifestyle-related human diseases and 
show that DJ-1 plays a key role in glucose 
homeostasis (Jain et al., 2012). 
Stroke 
Loss of DJ-1 increases the sensitivity to 
excitotoxicity and ischemia, whereas expression of 
DJ-1 can reverse this sensitivity and provide 
protection (Aleyasin et al., 2007). Importantly, DJ-1 
expression decreases markers of oxidative stress 
after stroke insult in vivo, suggesting that DJ-1 
protects through alleviation of oxidative stress 
(Aleyasin et al., 2007). Consistent with this finding, 
(Aleyasin et al., 2007) demonstrated the essential 
role of the oxidation-sensitive cysteine-106 residue 
in the neuroprotective activity of DJ-1 after stroke. 
Prostate cancer 
he intracellular level of the DJ-1 polypeptide in 
prostatic benign hyperplasia BPH-1 cells is inducible 
and results markedly increased after exposure to 
stress-inducing agents (H 2 O 2 and mitomycin C). 
The expression of DJ-1 is relatively high in PC-3 
cells at the constitutive level, and incubation with the 
same cytotoxic drugs does not further modulate the 
polypeptide expression. Both cytotoxic agents 
activate the apoptotic pathway in the benign 
prostatic cells but not in PC-3 cells, which are 
resistant to their action (Hod, 2004). 
Renal carcinoma 
The expression level of DJ-1 mRNA in a series of 
176 renal cell carcinomas (RCC) has been measured 
by (Sitaram et al., 2009). The level of DJ-1 has been 
demonstrated significantly elevated in clear cell 
RCC compared with papillary RCC and kidney 
cortex tissue. 
Hepatocellular carcinoma 
DJ-1 was found significantly up-regulated in 149 
hepatocellular carcinomas (HCC). DJ-1 expression 
correlates with preoperative alpha-fetoprotein, liver 
cirrhosis, vein invasion, differentiation and overall 
survival, thus suggesting DJ-1 as a candidate 
prognostic biomarker of HCC (S. Liu et al., 2010). 
Ovarian carcinoma 
The expression and clinical role of DJ-1 and its 
putative association with transcriptional regulators 
specific proteins (SP1 and SP3) were investigated in 
ovarian carcinoma by (Davidson et al., 2008). RT-
PCR reactions and immunohistochemistry were used 
to analyze the expression levels of DJ-1, Sp1 and 
Sp3 mRNAs and PTEN protein. DJ-1 expression 
resulted positively associated with Sp1 expression in 
effusions, and with Sp1 and Sp3 expression in solid 
tumors. Overall, results show DJ-1 is frequently 
expressed in advanced-stage ovarian carcinoma at all 
anatomical sites and is co-expressed with its 
transcriptional regulators Sp1 and Sp3. In contrast, 
PTEN expression is infrequent in this disease. 
Breast cancer 
Expression of DJ-1 was examined by 
immunohistochemistry and in-situ hybridization in 
273 breast invasive ductal carcinomas (IDCs) and 41 
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breast ductal carcinomas in situ (DCISs) and in 
cancer cell lines (MDA-MB-231). DJ-1 protein 
expression resulted lower than adjacent non-
cancerous epithelium in 6 of the 41 DCISs and in 146 
of the 273 IDCs. Patients with IDC and low DJ-1 
expression had significant shorter disease-free 
survival and overall survival. Low expression of DJ-
1 protein seems to be predictive of poor outcome in 
patients with IDC (Tsuchiya et al., 2012). 
Furthermore, RS/DJ-1 was found to be secreted in 
the breast cell line SUM-44 and in sera of diagnosed 
patients with breast cancer (Le Naour et al., 2001). 
Acute leukemia 
DJ-1 was found overexpressed in acute leukemia 
(AL) patient samples and leukemia cell lines, giving 
the first clue that DJ-1 overexpression might be 
involved in leukemogenesis and/or disease 
progression of AL (H. Liu et al., 2008). Inactivation 
of DJ-1 by RNA-mediated interference (RNAi) in 
leukemia cell lines K562 and HL60 resulted in 
inhibition of the proliferation potential and 
enhancement of the sensitivity of leukemia cells to 
chemotherapeutic drug etoposide(H. Liu et al., 
2008). 
Cervical cancer 
Normal cervical epithelium and patient-matched 
high-grade squamous intraepithelial lesions (HSIL) 
with cervical carcinoma tissue were compared by 
using laser capture microdissection and 2-D DIGE 
(Arnouk et al., 2009). Significant expression 
changes were observed with 53 spots corresponding 
to 23 unique proteins, including DJ-1. Results were 
confirmed by immunohistochemistry using either 
frozen sections from the same cohort or formalin 
fixed paraffin embedded samples from a tissue 
microarray. These markers can have potential 
applications for increasing the predictive value of 
current screening methods (Arnouk et al., 2009). 
Non-small cell lung carcinoma 
A proteomic approach using two-dimensional gels 
coupled with mass spectrometry was used in non-
small cell lung carcinoma samples to identify 
proteins altered when treated with paclitaxel, a 
chemotherapic that activates mitogen-activated 
protein kinase kinase (MEK)/extracellular signal-
regulated kinase and a MEK inhibitor (MacKeigan 
et al., 2003). This combined treatment uniquely 
altered the proteins RS/DJ-1 (RNA-binding 
regulatory subunit/DJ-1 PARK7) and RhoGDIalpha 
(MacKeigan et al., 2003). 
Endometrial cancer 
RT-PCR and Western blotting were performed to 
determine the DJ-1 expression in 100 surgical 
specimens of endometrial cancer tissues, paired 
tumor-adjacent tissues, and 30 surgical specimens of 
normal endometrium tissues (Morelli et al., 
2014).DJ-1 expression in endometrial cancer tissues 
was higher than in tumor-adjacent tissues and 
normal endometrial tissues. At the same time, it was 
associated with signs of cancer progression, 
including differentiation, myometrial invasion 
depth, and presence of lymph node metastasis. 
Overall, high DJ-1 expression seems to be negatively 
correlated with apoptosis, and it may be part of the 
mechanisms for the development, invasion, and 
metastasis in endometrial cancer (Morelli et al., 
2014). 
Thyroid cancer 
A comparative proteome analysis was performed by 
(Giusti et al., 2008) in order to examine the global 
changes of fine needle aspiration fluid protein 
patterns of two variants of malignant papillary 
thyroid cancer PTC (classical variant and tall cell 
variant) respect to the controls. Changes in protein 
expression were identified using two-dimensional 
electrophoresis (2DE) and peptide mass finger 
printing via MALDI-TOF mass spectrometry (MS), 
as well as Western blot analysis. A significant 
statistical up-regulation of 17 protein spots including 
DJ-1 was observed in classical PTC and/or tall cell 
variant PTC with respect to controls(Giusti et al., 
2008). 
Pancreas adenocarcinoma 
To identify potential novel biomarkers for pancreatic 
ductal adenocarcinoma (PDAC) from pancreatic 
juice, (Tian et al., 2008) carried out gel 
electrophoresis (DIGE) and tandem mass 
spectrometry (MS/MS) to compare the pancreatic 
juice profiling from 9 PDAC patients and 9 cancer-
free controls. Of the differently expressed proteins, 
three up-regulated proteins in pancreatic cancer juice 
were selected for validation by Western blot and 
immunohistochemistry, including DJ-1. Up-
regulation of DJ-1 was associated with better 
differentiation (Tian et al., 2008). In another study, 
the DJ-1 protein expression in tissue specimens from 
41 patients was evaluated by immunohistochemistry 
and associated with a negative impact of 
chemotherapy with gemcitabine on patient's 
survival. Therefore, DJ-1 has been suggested as 
prognostic markers that express resistance of 
pancreatic cancer patients to chemotherapy with 
gemcitabine (Tsiaousidou et al., 2013). 
Laryngeal squamous cell carcinoma 
A study conducted by (Shen et al., 2011)aimed to 
explore the correlation between DJ-1 gene and 
survivin gene BIRC5 in laryngeal squamous cell 
carcinoma. The expression levels of DJ-1 gene and 
survivin gene in 82 laryngeal carcinoma tissues from 
patients and 82 negative surgical margin tissue 
samples were measured by immunohistochemistry 
and the relationship with clinicopathologic 
parameters was assessed. Positive correlations were 
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found between expression levels and patients' 
clinical parameters in laryngeal carcinoma tissues 
and tumor stages, but not with lymph node 
metastasis. The DJ-1 gene expression level was also 
related to cell differentiation. DJ-1 and survivin play 
a vital role in the occurrence and development of 
laryngeal carcinoma. DJ-1 may promote the 
carcinogenesis of laryngeal cells by up-regulating 
the survivin gene expression (Shen et al., 2011). 
Esophageal squamous cell 
carcinoma 
The expression of DJ-1 in 81 esophageal squamous 
cell carcinoma (ESCC) tumors, 31 paired non 
neoplastic esophageal epithelia, and 19 paired ESCC 
lymph node metastases was analyzed by (Yuen et al., 
2008). They found that cytoplasmic DJ-1 expression 
was significantly higher in ESCC and ESCC lymph 
node metastases than in non neoplastic esophageal 
epithelium. ESCC specimens with high distant 
metastatic potential also had a significantly higher 
level of nuclear DJ-1 expression. A high level of 
nuclear DJ-1 was significantly associated with 
poorer patient survival in the cohort (P = 0.028). DJ-
1 expression was significantly associated with pAkt, 
whereas nuclear DJ-1 expression was significantly 
correlated with nuclear expression of DAXX. These 
results suggest that phosphatidylinositol 3-kinase 
pathway and Daxx-regulated apoptosis might be 
important in DJ-1-mediated ESCC progression. In 
conclusion, results suggest that DJ-1 plays a very 
important role in transformation and progression of 
ESCC and may be used as a prognostic marker in 
ESCC. 
Other malignancies 
Increased levels of DJ-1 expression have been 
observed in other kinds of cancer cells and tissues, 
including gastric cancer (Shimwell et al., 2012; Li et 
al., 2013), supraglottic cancer (Zhu et al., 2012), 
cholangiocarcinoma (Kawase et al., 2009), 
glioma/glioblastomas(Hinkle et al., 2011; Wang et 
al., 2013), bladder carcinoma (Lee et al., 2012) and 
melanoma (Pardo et al., 2006). Increased levels of 
DJ-1 expression in cancer cells are parallel to 
severity of cancer with poor prognosis, including 
metastasis and invasion (Ariga, 2015). 
To be noted 
COMPARTMENTS (compartments.jensenlab.org) 
is any updated web resource that integrates evidence 
on protein subcellular localization from manually 
curated literature, high-throughput screens, 
automatic text mining, and sequence-based 
prediction methods. It can be useful to display, with 
a certain grade of confidence, the subcellular 
localization of a specific biological molecule.  
PROTEOMICSDB (www.proteomicsdb.org) 
enables navigation of proteomes, provides biological 
insight and fosters the development of proteomic 
technology, and is a good tool to visualize the tissue 
distribution of mRNAs and proteins in human. 
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